Comprehensive evaluation of haemostatic function in von Willebrand disease patients using a microchip‐based flow chamber system

Patients with von Willebrand disease (VWD), including asymptomatic type 1, symptomatic type 1, type 2A, type 2N, and type 3.

Evaluation of haemostatic function using a microchip-based flow chamber system (collagen-coated PL-chip and collagen/thromboplastin-coated AR-chip), including in vitro addition of FVIII or VWF/FVIII and in vivo treatment with desmopressin or VWF/FVIII.

Platelet thrombus formation at 1000 s(-1) and fibrin-rich platelet thrombus formation at 240 s(-1)surrogate